About: Real-time IP-10 measurements as a new tool for inflammation regulation within a clinical decision support protocol for managing severe COVID-19 patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Real-time IP-10 measurements as a new tool for inflammation regulation within a clinical decision support protocol for managing severe COVID-19 patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Real-time IP-10 measurements as a new tool for inflammation regulation within a clinical decision support protocol for managing severe COVID-19 patients
Creator	Tadmor, Boaz Boico, Olga Navon, Roy Oved, Kfir Simon, Einav Gottlieb, Tanya Lev, Shaul Angel, Alon Avni, Noa Barash, Eran Ber, Tahel Berkov, Evgeny Diker, Dror Gelman, Amir Gottesman, Tamar Hainrichson, Mary Israeli, Yael Kalfon, Roy Kellerman, Lior Lederfein, Doron Levin, Gal Nutman, Amir Rosenberg, Michal Zaidman, Aliza Zarchin, Oren
Source	MedRxiv
abstract	The challenge of treating severely ill COVID-19 patients is particularly great due to the need to simultaneously manage oxygenation and the inflammatory state without compromising viral clearance. Currently, there are many tools to aid in oxygen management and in monitoring viral replication. However, predictive biomarkers for monitoring the host immune response across COVID-19 disease stages and specifically, for titrating immunomodulatory therapy are lacking. We utilized a recently cleared platform (MeMed Key) that enables rapid and easy serial measurement of IP-10, a host protein implicated in lung injury due to viral-induced hyperinflammation. A dynamic clinical decision support protocol was employed for managing SARS-CoV-2 positive patients admitted to a COVID-19 dedicated medical center run by Clalit Health Services. This is the first protocol to include real-time measurements of IP-10 as a potential aid for regulating inflammation. Overall, 502 serial real-time IP-10 measurements were performed on 52 patients recruited between 7th April 2020 to 10th May 2020, with 12 patients admitted to the intensive care unit (ICU). IP-10 levels correlated with increased COVID-19 severity score and ICU admission. Within the ICU admitted patients, the number of days with IP-10 measurements >1,000 pg/ml was associated with mortality. Upon administration of corticosteroid immunomodulatory therapy, a significant decrease in IP-10 levels was observed. Real-time IP-10 monitoring represents a new tool to aid in management and therapeutic decisions relating to the inflammatory status of COVID-19 patients.
has issue date	2020-07-22(xsd:dateTime)
bibo:doi	10.1101/2020.07.21.20158782
has license	medrxiv
sha1sum (hex)	1ca5b7ce367a0063043dc4166e74a57c01567525
schema:url	https://doi.org/10.1101/2020.07.21.20158782
resource representing a document's title	Real-time IP-10 measurements as a new tool for inflammation regulation within a clinical decision support protocol for managing severe COVID-19 patients
resource representing a document's body	covid:1ca5b7ce367a0063043dc4166e74a57c01567525#body_text
is schema:about of	named entity 'regulation' named entity 'COVID-19' named entity 'inflammation' named entity 'IP-10' named entity 'clinical decision support' named entity 'COVID-19' named entity 'serum' named entity 'SARS-CoV-2' named entity 'IP-10' named entity 'ferritin' named entity 'qSOFA' named entity 'IP-10' named entity 'zinc' named entity 'prospective study' named entity 'ECMO' named entity 'methylprednisolone' named entity 'IP-10' named entity 'IP-10' named entity 'refractory' named entity 'afebrile' named entity 'June 24' named entity 'acute lung injury' named entity 'thrombosis' named entity 'host-pathogen interaction' named entity 'COVID' named entity 'mortality rate' named entity 'cytokines' named entity 'BMI' named entity 'protein' named entity 'echocardiography' named entity 'Israel' named entity 'candidemia' named entity 'cohort study' named entity 'IP-10' named entity 'COVID' named entity 'IP-10' named entity 'RSV' named entity 'atelectasis' named entity 'IP-10' named entity 'immunomodulatory treatment' named entity 'IP-10' named entity 'IP-10' named entity 'tocilizumab' named entity 'titration' named entity 'ARDS' named entity 'IL-6' named entity 'IL-6' named entity 'IP-10' named entity 'Lactate dehydrogenase' named entity 'Python' named entity 'Europe' named entity 'tocilizumab' named entity 'viral infections' named entity 'immunomodulatory' named entity 'ICU' named entity 'prospective study' named entity 'oxygen delivery' named entity 'PCR' named entity 'protein' named entity 'anti-coagulation therapy' named entity 'ICU'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software